Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.
FlashNews:
FAA issues ground stop at airports in DC, Baltimore
Coinbase-backed AI payments protocol wants to fix micropayment but demand is just not there yet
YouTube expands access to AI detection tool to politicians and journalists
HollooStay Introduces a Smarter Global Hotel Booking Platform
HollooStay Introduces a Smarter Global Hotel Booking Platform
HollooStay Introduces a Smarter Global Hotel Booking Platform
HollooStay Introduces a Smarter Global Hotel Booking Platform
Pastor James Constable Announces Release of Amazing Devotional, The Narrow Way: Walking Daily with Jesus
Pastor James Constable Announces Release of Amazing Devotional, The Narrow Way: Walking Daily with Jesus
Pastor James Constable Announces Release of Amazing Devotional, The Narrow Way: Walking Daily with Jesus
Pastor James Constable Announces Release of Amazing Devotional, The Narrow Way: Walking Daily with Jesus
Pastor James Constable Announces Release of Amazing Devotional, The Narrow Way: Walking Daily with Jesus
Spawned Launches Solana Tokens in Minutes, No Dev Team Required
Spawned Launches Solana Tokens in Minutes, No Dev Team Required
Spawned Launches Solana Tokens in Minutes, No Dev Team Required
Spawned Launches Solana Tokens in Minutes, No Dev Team Required
Spawned Launches Solana Tokens in Minutes, No Dev Team Required
Texas university’s sudden cancellation of exhibition with works critical of Ice sparks censorship row
Pastor James Constable Announces Release of Amazing Devotional, The Narrow Way: Walking Daily with Jesus
Home » Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.